IRIS UniCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.995
NA - Nord America 3.879
AS - Asia 2.299
SA - Sud America 434
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
AN - Antartide 1
Totale 11.678
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.775
DE - Germania 1.249
IT - Italia 1.224
SG - Singapore 1.082
CN - Cina 680
SE - Svezia 595
FR - Francia 478
PL - Polonia 449
BR - Brasile 355
UA - Ucraina 330
GB - Regno Unito 186
IE - Irlanda 140
IN - India 122
FI - Finlandia 90
ID - Indonesia 84
VN - Vietnam 80
NL - Olanda 72
RU - Federazione Russa 66
TR - Turchia 61
CA - Canada 52
AR - Argentina 41
JP - Giappone 31
BD - Bangladesh 29
HK - Hong Kong 29
MX - Messico 27
BE - Belgio 26
ZA - Sudafrica 20
IR - Iran 19
ES - Italia 17
IQ - Iraq 15
AT - Austria 11
LT - Lituania 10
EC - Ecuador 9
EG - Egitto 8
JM - Giamaica 8
SA - Arabia Saudita 8
VE - Venezuela 8
CH - Svizzera 7
CZ - Repubblica Ceca 7
KE - Kenya 7
PK - Pakistan 7
AZ - Azerbaigian 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
MA - Marocco 6
PE - Perù 6
PY - Paraguay 5
UZ - Uzbekistan 5
DK - Danimarca 4
HN - Honduras 4
JO - Giordania 4
PA - Panama 4
PH - Filippine 4
PT - Portogallo 4
TN - Tunisia 4
BG - Bulgaria 3
CL - Cile 3
DZ - Algeria 3
GR - Grecia 3
KR - Corea 3
LU - Lussemburgo 3
NI - Nicaragua 3
RO - Romania 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HR - Croazia 2
HU - Ungheria 2
IM - Isola di Man 2
KG - Kirghizistan 2
LB - Libano 2
LK - Sri Lanka 2
MC - Monaco 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CD - Congo 1
CO - Colombia 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GH - Ghana 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MM - Myanmar 1
NC - Nuova Caledonia 1
NE - Niger 1
Totale 11.667
Salva come PNG Salva come JPEG
Città #
Chandler 653
Singapore 458
Kraków 426
Ashburn 382
Rome 287
Jacksonville 248
Milan 172
New York 171
San Mateo 156
Dublin 138
Nanjing 135
Ann Arbor 122
Beijing 98
Los Angeles 92
Dearborn 86
Nürnberg 83
Jakarta 82
Houston 81
Wilmington 76
Lawrence 71
Cattolica 66
Woodbridge 62
Boston 59
Nanchang 57
Lancaster 53
Dallas 51
Redmond 50
Izmir 46
Redwood City 42
Seattle 37
The Dalles 36
Hefei 34
Shenyang 34
Verona 32
Moscow 31
Boardman 30
Ho Chi Minh City 29
Buffalo 28
Hong Kong 28
Munich 28
Frankfurt am Main 27
Brussels 26
Bremen 25
Kunming 25
Naples 25
Tokyo 24
Changsha 23
Fairfield 23
Mountain View 23
São Paulo 23
Hebei 22
Norwalk 21
Falls Church 20
Hanoi 20
Santa Clara 19
Düsseldorf 18
Ottawa 18
Shanghai 18
Turin 18
Warsaw 18
Leawood 17
University Park 17
Augusta 15
Marseille 15
Bologna 14
Tianjin 14
Brooklyn 13
Guangzhou 13
Hangzhou 13
Jinan 13
London 13
Montreal 13
Rio de Janeiro 13
Toronto 13
Chicago 12
Fremont 12
Pune 12
Bari 11
Lauterbourg 11
Poplar 11
Roubaix 11
Washington 11
Johannesburg 10
Atlanta 9
Brasília 9
Helsinki 9
Orem 9
Simi Valley 9
Stockholm 9
Amsterdam 8
Bexley 8
Kent 8
Phoenix 8
Portsmouth 8
Princeton 8
Zhengzhou 8
Belo Horizonte 7
Cambridge 7
Changchun 7
Chennai 7
Totale 5.721
Salva come PNG Salva come JPEG
Nome #
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 1.159
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 253
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 236
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 212
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 210
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 205
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 199
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 191
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 188
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 182
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 180
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 177
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 170
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 164
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 162
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 161
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 159
Variability of raltegravir plasma levels in the clinical setting 158
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 158
Initial antifungal strategy does not correlate with mortality in patients with candidemia 156
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 155
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 154
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 150
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 144
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 144
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 142
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 142
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 142
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 140
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 140
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 139
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 138
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 138
Cognitive reserve and neuropsychological functioning in older HIV-infected people 138
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 137
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 136
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 134
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 134
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 134
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 133
Effect of aging and human immunodeficiency virus infection on cognitive abilities 133
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 132
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 131
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 130
Immune response to influenza A(H1N1)v in HIV-infected patients 129
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 128
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 127
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 127
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 127
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 126
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 126
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 125
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 123
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 122
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 119
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 118
Lipid-lowering effect of tenofovir in HIV-infected patients 115
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 115
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 113
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 113
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 111
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 110
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 109
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 106
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 106
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 105
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 103
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 102
Immune response to influenza A(H1N1)v in HIV-infected patients 99
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 98
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 86
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 79
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 79
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 76
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 75
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 74
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 66
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 62
Totale 11.755
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021403 0 0 0 0 0 37 76 16 115 22 121 16
2021/2022806 77 64 25 61 47 40 21 129 29 73 121 119
2022/20231.639 237 261 132 258 136 191 29 145 186 11 39 14
2023/20241.021 41 231 30 106 45 212 68 22 30 50 116 70
2024/20251.913 55 55 120 103 222 89 99 160 332 154 294 230
2025/20262.088 570 97 200 442 721 58 0 0 0 0 0 0
Totale 11.755